{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:14:18Z","timestamp":1781129658957,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016250","name":"New York Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI164233"],"award-info":[{"award-number":["R21 AI164233"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.vaccine.2025.127306","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:48:40Z","timestamp":1748281720000},"page":"127306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1\/Th17 skewed localized and systemic immune response."],"prefix":"10.1016","volume":"60","author":[{"given":"Adiya S.","family":"Katseff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Toumanios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Barahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison A.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Arnaboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127306_bb0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127306_bb0010","first-page":"9","article-title":"Understanding Pseudomonas aeruginosa-host interactions: the ongoing quest for an efficacious vaccine","author":"Sainz-Mej\u00edas","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.vaccine.2025.127306_bb0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/21645515.2019.1650999","article-title":"Immunological considerations in the development of Pseudomonas aeruginosa vaccines","volume":"16","author":"Baker","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127306_bb0020","series-title":"HAI Pathogens and Antimicrobial Resistance Report, 2018\u20132021","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127306_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127306_bb0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.burns.2015.10.030","article-title":"Antibiotic consumption to detect epidemics of Pseudomonas aeruginosa in a burn Centre: a paradigm shift in the epidemiological surveillance of Pseudomonas aeruginosa nosocomial infections","volume":"42","author":"Fournier","year":"2016","journal-title":"Burns"},{"key":"10.1016\/j.vaccine.2025.127306_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/CMR.19.2.403-434.2006","article-title":"Burn wound infections","volume":"19","author":"Church","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2025.127306_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0140-6736(98)09385-4","article-title":"Incidence of contact-lens-associated microbial keratitis and its related morbidity","volume":"354","author":"Cheng","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127306_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2025.127306_bb0050","series-title":"Antibiotic resistance threats in the United States, 2019","author":"U.S. Centers for Disease Control and Prevention","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127306_bb0055","series-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.vaccine.2025.127306_bb0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: Potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0065","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0264-410X(98)00441-1","article-title":"Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview","volume":"17","author":"Kyd","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127306_bb0070","first-page":"8","article-title":"Humans have antibodies against a plant virus: evidence from tobacco mosaic virus","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127306_bb0075","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.vaccine.2014.04.051","article-title":"Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo","volume":"32","author":"Kemnade","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127306_bb0080","first-page":"11","article-title":"Modulation of immune responses by particle size and shape","author":"Baranov","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0090","first-page":"5","article-title":"Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination","author":"Li","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127306_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14760584.7.1.33","article-title":"Genetically engineered tobacco mosaic virus as nanoparticle vaccines","volume":"7","author":"McCormick","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127306_bb0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.virol.2005.12.039","article-title":"Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications","volume":"348","author":"Smith","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127306_bb0105","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1073\/pnas.96.14.7774","article-title":"Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope","volume":"96","author":"Koo","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.127306_bb0110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4161\/hv.27567","article-title":"Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge","volume":"10","author":"Mallajosyula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127306_bb0115","first-page":"13","article-title":"Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge","author":"McCormick","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127306_bb0120","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0264-410X(99)00571-X","article-title":"Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. Aeruginosa","volume":"18","author":"Staczek","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127306_bb0125","first-page":"9","article-title":"Development of a SARS-CoV-2 vaccine candidate using plant-based manufacturing and a tobacco mosaic virus-like Nano-particle","author":"Royal","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127306_bb0130","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.vaccine.2016.09.063","article-title":"Intranasal delivery of a protein subunit vaccine using a tobacco mosaic virus platform protects against pneumonic plague","volume":"34","author":"Arnaboldi","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127306_bb0135","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.vaccine.2021.01.040","article-title":"Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection","volume":"39","author":"D\u2019Arco","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127306_bb0140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.201202-0182OC","article-title":"Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia","volume":"186","author":"Wu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2025.127306_bb0145","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1128\/IAI.00717-16","article-title":"Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa","volume":"84","author":"Bayes","year":"2016","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127306_bb0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2002.01731.x","article-title":"Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response","volume":"127","author":"Moser","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0155","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2016.05.011","article-title":"Targeting the type three secretion system in Pseudomonas aeruginosa","volume":"37","author":"Anantharajah","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2025.127306_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JB.00050-19","article-title":"Pushing beyond the envelope: the potential roles of OprF in Pseudomonas aeruginosa biofilm formation and pathogenicity","volume":"201","author":"Cassin","year":"2019","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0165","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1128\/IAI.00081-15","article-title":"Identification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosa","volume":"83","author":"Mishra","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127306_bb0170","first-page":"8","article-title":"Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I\/II study","author":"Baumann","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.vaccine.2025.127306_bb0175","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.4049\/jimmunol.0902477","article-title":"Involvement of the NLRP3 Inflammasome in innate and humoral adaptive immune responses to fungal \u03b2-glucan","volume":"183","author":"Kumar","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0180","first-page":"5","article-title":"Human dendritic cells activated via dectin-1 are efficient at priming th17, cytotoxic CD8 T and B cell responses","author":"Agrawal","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127306_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jps.22267","article-title":"Acceptable levels of endotoxin in vaccine formulations during preclinical research","volume":"100","author":"Brito","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2025.127306_bb0190","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/jps.21152","article-title":"Endotoxin limits in formulations for preclinical research","volume":"97","author":"Malyala","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2025.127306_bb0195","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.vaccine.2006.04.058","article-title":"Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes","volume":"24","author":"Palmer","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127306_bb0200","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejpb.2012.03.013","article-title":"Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone","volume":"81","author":"Barnier Quer","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2025.127306_bb0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","article-title":"Colorimetric determination of phospholipids with ammonium Ferrothiocyanate","volume":"104","author":"Stewart","year":"1980","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2025.127306_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J Virol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4939-0473-0_14","article-title":"In vitro assays to monitor the activity of Pseudomonas aeruginosa type III secreted proteins","volume":"1149","author":"Rolsma","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0220","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06670.017","article-title":"The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo","author":"Blaauboer","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2025.127306_bb0225","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4161\/21645515.2014.971641","article-title":"Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa","volume":"10","author":"Sawa","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127306_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01781-24","article-title":"Effects of the combination of anti-PcrV antibody and bacteriophage therapy in a mouse model of Pseudomonas aeruginosa pneumonia","volume":"12","author":"Junya","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2025.127306_bb0235","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.4049\/jimmunol.167.10.5880","article-title":"Therapeutic administration of anti-PcrV F(ab\u2019)(2) in sepsis associated with Pseudomonas aeruginosa","volume":"167","author":"Shime","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-8518-1-2","article-title":"Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model","volume":"1","author":"Faure","year":"2003","journal-title":"J Immune Based Ther Vaccines"},{"key":"10.1016\/j.vaccine.2025.127306_bb0245","doi-asserted-by":"crossref","first-page":"1899549","DOI":"10.1080\/21645515.2021.1899549","article-title":"Antibody-dependent passive protection of mucosal surfaces","volume":"18","author":"Mestecky","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127306_bb0250","first-page":"362","article-title":"A role for CD4 + T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung","volume":"83","author":"Dunkley","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2025.127306_bb0255","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/IAI.00501-09","article-title":"Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia","volume":"77","author":"Koh","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127306_bb0260","series-title":"In Vitro Response of Human T Cells to Pseudomonas aeruginosa","volume":"40","author":"Porwoll","year":"1983"},{"key":"10.1016\/j.vaccine.2025.127306_bb0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1164\/rccm.202308-1403OC","article-title":"A bispecific monoclonal antibody targeting Psl and PcrV enhances neutrophil-mediated killing of Pseudomonas aeruginosa in patients with bronchiectasis","volume":"210","author":"Long","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2025.127306_bb0270","first-page":"178","article-title":"A chimeric vaccine targeting Pseudomonas aeruginosa virulence factors protects mice against lethal infection","author":"Korpi","year":"2023","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2025.127306_bb0275","first-page":"8","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127306_bb0280","first-page":"11","article-title":"Development of a chimeric vaccine against Pseudomonas aeruginosa based on the Th17-stimulating epitopes of PcrV and AmpC","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0285","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1146\/annurev.immunol.20.103001.114744","article-title":"Phagocytosis of microbes: complexity in action","volume":"20","author":"Underhill","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127306_bb0290","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2005.09.013","article-title":"Cell surface recycling of internalized antigen permits dendritic cell priming of B cells","volume":"23","author":"Bergtold","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.127306_bb0295","first-page":"6","article-title":"IL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa","author":"Lor\u00e8","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127306_bb0300","first-page":"24","article-title":"Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients - a randomized clinical trial","author":"Adlbrecht","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.vaccine.2025.127306_bb0305","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2052-0492-2-10","article-title":"The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response","volume":"2","author":"Sawa","year":"2014","journal-title":"J Intensive Care"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25006036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25006036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:19:04Z","timestamp":1749122344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25006036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"alternative-id":["S0264410X25006036"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127306","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1\/Th17 skewed localized and systemic immune response.","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127306"}}